Exporters compete on price, and part of that price is made up of domestic taxes that no other mechanism returns to them.
The Extreme Poverty Eradication Project, also known as the Athidaridrya Nirmarjana Project, was launched by the Government of Kerala in 2021 under the Local Self Government Department (LSGD). Its goal was to find people living in extreme poverty who had fallen outside existing support systems and help them exit that condition within five years (LSGD). Sources provide different launch months, ranging from May to July 2021, so the exact date still needs to be verified with the government order.
The EPFO, established in 1952, is one of the world's largest social security institutions, committed to social security for the financial future of India's workforce. EPFO is a managed provident fund, pension and insurance scheme for workers in the organised sector through its 3 flagship schemes — The EPF scheme (1952), The EPS (1995), the EDLI scheme (1976).
India and Brazil have had diplomatic relations since 1948, and their relationship was elevated to a Strategic Partnership in 2006. Since then, cooperation has expanded into areas such as trade, science and technology, energy and digital development. Building on this broader relationship, the two countries have now strengthened cooperation in telecommunications and Information and Communication Technologies, or ICTs.
The persistent narrative of youth apathy towards politics has become empirically untenable in contemporary India.
India's biotechnology sector has expanded significantly over the past decade, with the bioeconomy growing from $10 billion in 2014 to $165.7 billion in 2024, accounting for approximately 4.25% of GDP. And the target? $300 billion by 2030 (PIB, 2025)[2]. Recent global supply-chain disruptions, particularly during the COVID-19 pandemic, exposed India's dependence on imported biological inputs and reinforced the need for domestic biomanufacturing capacity. But strong science alone won’t make India an industry leader.
The growing use of Ayurveda, Siddha, Unani and Homoeopathy (ASU&H) medicines has increased the need for effective mechanisms to monitor their safety and regulate their promotion. Two major concerns necessitate stronger surveillance: the under-reporting or delayed identification of Adverse Drug Reactions (ADRs) and the circulation of misleading or objectionable advertisements making unsubstantiated therapeutic claims. Without systematic reporting, documentation and analysis, potential safety signals may remain unidentified, while misleading claims can influence consumer decisions and expose patients to health risks. Addressing these concerns requires coordinated monitoring, reliable reporting mechanisms and timely referral of complaints to the appropriate regulatory authorities.